Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Table 4 Healthcare cost outcomes for the provincial drug coverage subset (n = 113)

	Mean annual HCRU cost per patient ($CAD)
Real-world cost outcome	Pre-mepolizumab	Post-mepolizumab	% change
GP visit (asthma-related)	$98.97	$70.02	–29.3
Specialist visit (asthma-related)	$400.01	$259.57	–34.7***
ED visits (all-cause)	$845.35	$724.50	–14.3
Hospital admission (all-cause)^†	$5,381.49	$3,569.75	–33.7
HCRU (excluding drug cost)^‡	$7,565.79	$5,205.87	–31.2
Drug cost (asthma-related)	$3,679.92	$4,152.60	+ 11.4
HCRU (including drug cost)	$11,245.71	$9,358.47	–16.8

***P < 0.001
^†Due to resource intensity weighting, costs cannot be accurately estimated from specific hospital admission reasons; thus, costs are not asthma-specific
^‡HCRU includes all factors listed in table as well as other asthma-related physician costs for shadow billings, where the location was other than home, office, or phone
$CAD, Canadian dollars; ED, emergency department; GP, general practitioner; HCRU, healthcare resource utilization

ISSN: 1710-1492